Altered Amyloid Plasma Profile in Patients with Debilitating Headaches After SARS-CoV-2 Infection and Vaccination#

The Underestimated Side Effect#

Headaches are a very common side effect of modRNA injections. In the case of BNT162B2, headaches are particularly prominent in PSUR 3. They initially appear to be a negligible side effect, since everyone experiences headaches occasionally and there are many causes for them. However, in some patients, these headaches persist permanently for months. A case that has resulted in legal action shows that the cause may not be as harmless as it seems.

A new publication titled “Altered Amyloid Plasma Profile in Patients with Debilitating Headaches After SARS-CoV-2 Infection and Vaccination” investigates this phenomenon. The study shows that both infected and “vaccinated” individuals are affected, pointing to the spike protein as a common cause.

Study Design and Methodology#

In a prospective observational study, 29 patients after COVID-19 illness and 31 patients after SARS-CoV-2 vaccination who suffered from severe headaches were examined. They were re-examined after six months. Four proteins were studied as blood markers: amyloid precursor protein (APP), pregnancy zone protein (PZP), cathepsin L1 (CTSL), and serum amyloid A (SAA1).

The Investigated Biomarkers#

APP (Amyloid Precursor Protein): APP is an integral membrane protein that serves as the starting material for beta-amyloid biosynthesis and may play a role in Alzheimer’s disease. It was selected as a marker because it is also a receptor for SARS-CoV-2.

PZP (Pregnancy Zone Protein): PZP plays a role in immune regulation during pregnancy and has been proposed as a marker for various inflammatory diseases, including COVID-19 prognosis.

CTSL (Cathepsin L1): CTSL is a lysosomal cysteine protease that facilitates intracellular protein catabolism and facilitates SARS-CoV-2 virus entry into host cells.

SAA1 (Serum Amyloid A): SAA1 is an acute phase protein and systemic inflammation marker originally identified as a biomarker for poor prognosis in COVID-19.

Key Study Results#

The study identified altered plasma levels of soluble markers indicating disturbed amyloid processing in patients with persistent headaches after SARS-CoV-2 vaccination. Particularly notable was that:

  • APP was elevated in patients with headaches after COVID-19
  • PZP was elevated in patients with headaches after vaccination

This suggests that the cause of headaches may be different depending on infection or vaccination, although the spike protein is suspected as the triggering factor in both cases.

For lawyers, this represents an important breakthrough: Persistent headaches after vaccination can now be biochemically proven, provided one can find someone who can measure these two proteins. This provides at least something measurable so that the client is not dismissed into the “psychological corner.”

  • Elevated PZP: Indicates vaccine injury
  • Elevated APP: Indicates virus infection-related damage
  • Measurable biomarkers: Objective evidence instead of subjective complaints

If the infection occurred only after “vaccination,” it could still be vaccine damage because one contracted the virus due to being vaccinated - but this will be much more difficult to prove in court than simply having a high PZP value.

Significance for Affected Patients#

For affected individuals, this represents important validation: There are measurable changes and they are not imagining it. The cause is not fully clarified, but something can be measured.

Practical Consequences:#

  • Validation: Objective confirmation of complaints
  • Diagnostics: Measurable parameters for persistent headaches
  • Protection: Defense against psychosomatization of complaints

Therapeutically, this is not really helpful, but at least it provides a measurable value to prove that one is not imagining it and is not crazy.

Scientific Classification and Outlook#

The authors explicitly emphasize that these results are speculative and further studies are needed to clarify the cause and consequences of elevated protein levels in patients with persistent headaches after COVID-19.

Open Questions:#

  • Long-term effects: What permanent damage results from amyloid changes?
  • Therapeutic approaches: How can the biochemical changes be treated?
  • Prevalence: How frequently do these changes actually occur?

The Spike Protein as Common Denominator#

In both COVID-19 infections and mRNA vaccinations, the spike protein is the common factor. However, the different biomarker profiles (APP vs. PZP) suggest that the mechanisms of action could be different:

  • In infection: Direct viral attack on various organ systems
  • In vaccination: Immune reaction to artificially produced spike protein

Neurological Implications and Alzheimer’s Connection#

The involvement of APP is particularly concerning given its role in Alzheimer’s disease pathology. The elevation of this protein in headache patients suggests potential long-term neurological consequences that warrant serious investigation.

Potential Mechanisms:#

  • Neuroinflammation: Chronic inflammatory processes in the brain
  • Protein misfolding: Disruption of normal amyloid processing
  • Vascular effects: Impact on cerebral blood flow and vessel integrity

Clinical Validation and Diagnostic Utility#

This study provides the first objective, laboratory-based evidence for persistent post-vaccination and post-infection headaches. The differential biomarker patterns offer potential for:

Diagnostic Applications:#

  • Causal attribution: Distinguishing infection-related from vaccination-related headaches
  • Severity assessment: Quantifying the degree of biochemical disruption
  • Monitoring: Tracking changes over time

The identification of specific biomarkers represents a paradigm shift in how vaccine-related adverse events can be documented and litigated:

  • Objective evidence: Moving beyond subjective symptom reports
  • Causality assessment: Biochemical fingerprints for different causes
  • Burden of proof: Shifting from patient testimony to laboratory data

For Regulatory Agencies:#

  • Surveillance enhancement: Improved post-marketing safety monitoring
  • Risk assessment: Better understanding of adverse event mechanisms
  • Policy implications: Evidence-based evaluation of benefit-risk profiles

Conclusion: A Critical Piece of the Puzzle#

This study provides the first measurable, biochemical evidence for persistent headaches after COVID-19 and mRNA vaccinations. While therapeutic options remain limited, this represents important progress for the recognition and legal evaluation of vaccine injuries.

The finding that different biomarkers are elevated in infection (APP) and vaccination (PZP) could help in the future to more precisely assign the cause of headaches, enabling both medically and legally more precise evaluation.

The implications extend beyond headaches to broader questions about spike protein toxicity, whether from natural infection or vaccination. As more research emerges, the distinction between these pathways may prove crucial for both treatment and prevention strategies.

Source: Dr. Sabine Stebel

The information presented in this article is for scientific information purposes only and does not replace professional medical or legal advice.